Literature DB >> 30915753

MiR-296-5p suppresses papillary thyroid carcinoma cell growth via targeting PLK1.

S-L Zhou1, Q-L Tang, S-X Zhou, R-Z Ren.   

Abstract

OBJECTIVE: Our study aimed to explore the effects of miRNA-296-5p on the biological behaviors of papillary thyroid carcinoma (PTC) cells and its potential mechanism. PATIENTS AND METHODS: Twenty-eight PTC tissues and the corresponding non-cancerous tissues were collected. Real Time-quantitative Polymerase Chain Reaction (RT-qPCR) analysis was performed to detect the expression levels of miR-296-5p in PTC tissues and the adjacent non-cancerous tissues. Besides, the different endogenous expression levels of miR-296-5p in PTC cell line (K1) and normal thyroid gland cell line (Nthy-ori3-1) were also detected by RT-qPCR. Bioinformatics analysis, Western blot and Dual-Luciferase reporter gene assay were performed to demonstrate whether polo-like kinase 1 (PLK-1) was a downstream target of miR-296-5p. Subsequently, MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) assay, flow cytometry analysis, colony formation assay and TUNEL assay were performed to estimate whether PLK1 down-regulation could attenuate the malignant behaviors of PTC cells in vitro.
RESULTS: RT-qPCR results showed that the expression level of miR-296-5p was significantly down-regulated in PTC tissues and cells, indicating that miR-296-5p may participate in PTC development. We predicted target genes of miR-296-5p by bioinformatics and identified PLK1 as a target gene of miR-296-5p. By Western blot and Dual-Luciferase reporter gene assay, we confirmed that miR-296-5p was partially complement to PLKl mRNA 3'UTR sequence and inhibited PLK1 expression at the post-transcriptional level. In vitro experiments suggested that the transfection of miR-296-5p mimics into K1 cells suppressed cell proliferation, inhibited cell clone formation, arrest the cell cycle in G2/M phase and induced apoptosis. Importantly, PLK1 reversed the inhibitory effects of miR-296-5p on biological behaviors of PTC.
CONCLUSIONS: MiR-296-5p influences the biological behaviors of PTC by regulating PLK1. These findings provide a new perspective for the molecular mechanism of PTC pathogenesis and also contribute to developing new targets and methods for PTC treatment.

Entities:  

Year:  2019        PMID: 30915753     DOI: 10.26355/eurrev_201903_17251

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  6 in total

1.  Identification of key genes in lung adenocarcinoma based on a competing endogenous RNA network.

Authors:  Zikun Song; Yinjiang Zhang; Zheren Chen; Bicheng Zhang
Journal:  Oncol Lett       Date:  2020-11-19       Impact factor: 2.967

2.  Exosomal circ_IFT80 Enhances Tumorigenesis and Suppresses Radiosensitivity in Colorectal Cancer by Regulating miR-296-5p/MSI1 Axis.

Authors:  Liang Li; Zhipeng Jiang; Xiangcai Zou; Tengfei Hao
Journal:  Cancer Manag Res       Date:  2021-02-24       Impact factor: 3.989

3.  lncRNA HOTAIRM1 regulates cell proliferation and the metastasis of thyroid cancer by targeting Wnt10b.

Authors:  Chenyao Li; Xinxin Chen; Tao Liu; Guang Chen
Journal:  Oncol Rep       Date:  2020-12-31       Impact factor: 3.906

4.  Deregulation of hsa_circ_0001971/miR-186 and hsa_circ_0001874/miR-296 signaling pathways promotes the proliferation of oral squamous carcinoma cells by synergistically activating SHP2/PLK1 signals.

Authors:  Wang Jun; Ouyang Shaobo; Zhang Xianhua; Zhao Siyu; Cheng Mingyang; Fan Xin; Cai Ying; Liao Lan
Journal:  Sci Rep       Date:  2021-10-18       Impact factor: 4.379

5.  lncRNA RUNDC3A-AS1 Regulates Proliferation and Apoptosis of Thyroid Cancer Cells via the miR-151b/SNRPB Axis.

Authors:  Yan Deng; Jie Wu; Xin Li
Journal:  Int J Endocrinol       Date:  2022-02-22       Impact factor: 3.257

6.  Circular RNA hsa_circ_001895 serves as a sponge of microRNA-296-5p to promote clear cell renal cell carcinoma progression by regulating SOX12.

Authors:  Zhuangfei Chen; Kanghua Xiao; Shijun Chen; Zehai Huang; Yunlin Ye; Tong Chen
Journal:  Cancer Sci       Date:  2019-12-30       Impact factor: 6.716

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.